CXCR3‐expressed T cells homing to tumor site play a crucial role in anti‐tumor immunity and anti‐PD‐1 treatment efficacy.[30, 31] Therefore, our research provides robust evidence for targeting epigenetic therapy to modulate anti‐tumor immune responses and enhance immunotherapy. The gene discussed is CXCR3; the disease is neoplasm.